Shopping Cart

Remove All

Your shopping cart is currently empty

INHBE Protein, Human, Recombinant (hFc)

Resource Download

INHBE Protein, Human, Recombinant (hFc)

Catalog No. TMPY-05029

INHBE (Inhibin Subunit Beta E) is a Protein Coding gene. This gene encodes a member of the TGF-beta (transforming growth factor-beta) superfamily of proteins. The encoded preproprotein is proteolytically processed to generate an inhibin beta subunit. INHBE was identified as a novel putative hepatokine with hepatic gene expression that positively correlated with insulin resistance and body mass index in humans. The quantitative real time-PCR analysis also showed an increase in INHBE gene expression in independent liver samples from insulin-resistant human subjects. INHBE functions as a possible hepatokine to alter the whole-body metabolic status under obese insulin-resistant conditions. Diseases associated with INHBE include Brachydactyly, Type A2, and Liver Benign Neoplasm.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Pack Size	Price	Availability	Quantity
100 μg	$539	7-10 days

Bulk & Custom

Add to Cart

Questions

Biological Description

Biological Information	Testing in progress
Description	INHBE (Inhibin Subunit Beta E) is a Protein Coding gene. This gene encodes a member of the TGF-beta (transforming growth factor-beta) superfamily of proteins. The encoded preproprotein is proteolytically processed to generate an inhibin beta subunit. INHBE was identified as a novel putative hepatokine with hepatic gene expression that positively correlated with insulin resistance and body mass index in humans. The quantitative real time-PCR analysis also showed an increase in INHBE gene expression in independent liver samples from insulin-resistant human subjects. INHBE functions as a possible hepatokine to alter the whole-body metabolic status under obese insulin-resistant conditions. Diseases associated with INHBE include Brachydactyly, Type A2, and Liver Benign Neoplasm.
Species	Human
Expression System	HEK293 Cells
Tag	N-hFc
Accession Number	P58166
Synonyms	inhibin beta E,inhibin β E
Construction	The Human INHBE (NP_113667.1) (Thr237-Ser350) was expressed with the Fc region of Human IgG1 at the N-terminus.
Protein Purity	> 90 % as determined by SDS-PAGE.
Molecular Weight	40.9 kDa (predicted)
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	INHBE (Inhibin Subunit Beta E) is a Protein Coding gene. This gene encodes a member of the TGF-beta (transforming growth factor-beta) superfamily of proteins. The encoded preproprotein is proteolytically processed to generate an inhibin beta subunit. INHBE was identified as a novel putative hepatokine with hepatic gene expression that positively correlated with insulin resistance and body mass index in humans. The quantitative real time-PCR analysis also showed an increase in INHBE gene expression in independent liver samples from insulin-resistant human subjects. INHBE functions as a possible hepatokine to alter the whole-body metabolic status under obese insulin-resistant conditions. Diseases associated with INHBE include Brachydactyly, Type A2, and Liver Benign Neoplasm.